Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0K6GZ
|
|||
Former ID |
DAP000161
|
|||
Drug Name |
Sparfloxacin
|
|||
Synonyms |
Esparfloxacino; SPFX; Spara; Sparfloxacine; Sparfloxacinum; Zagam; AT 4140; CP 103826; PD 131501; PD131501; AT-4140; CP-103826; DRG-0143; Esparfloxacino [INN-Spanish]; Liposome-encapsulated sparfloxacin; PD 1315-1; PD-131501; RP-64206; Respipac (TN); Sparfloxacin & RU 40555; Sparfloxacine [INN-French]; Sparfloxacinum [INN-Latin]; Zagam (TN); Sparfloxacin, cis-isomer; Sparfloxacin (JAN/USAN/INN); Sparfloxacin [USAN:BAN:INN:JAN]; Cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; (cis)-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclohexyl-7-(cis-3,5-dimethylpiperazino)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid & RU 40555; 5-Amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
Therapeutic Class |
Antibiotics
|
|||
Company |
Square pharma
|
|||
Structure |
Download2D MOL |
|||
Formula |
C19H22F2N4O3
|
|||
Canonical SMILES |
CC1CN(CC(N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
|
|||
InChI |
1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
|
|||
InChIKey |
DZZWHBIBMUVIIW-DTORHVGOSA-N
|
|||
CAS Number |
CAS 110871-86-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9864, 602967, 603315, 627689, 7847656, 7980640, 8147220, 8186880, 11528734, 12014309, 14830034, 16618671, 24860661, 24880518, 25623210, 26719819, 29218052, 43117868, 46386584, 46506453, 48416549, 56313707, 57314019, 57648946, 57651613, 78600880, 85279509, 92309275, 92710927, 103223807, 104225171, 104320846, 117393504, 124766044, 124893258, 125325629, 126631379, 126682799, 127811456, 131294555, 131905130, 134223183, 134337481, 135018692, 137003456, 142971059, 144205133, 160845924, 160964541, 163414061
|
|||
ChEBI ID |
CHEBI:9212
|
|||
ADReCS Drug ID | BADD_D02062 | |||
SuperDrug ATC ID |
J01MA09
|
|||
SuperDrug CAS ID |
cas=110871868
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacillales | ||||
Studied Microbe: Bacillus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bacillus was not significantly changed by Sparfloxacin. | |||
Studied Microbe: Staphylococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Staphylococcus was not significantly changed by Sparfloxacin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bacteroides was not significantly changed by Sparfloxacin. | |||
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides caccae was decreased by Sparfloxacin (adjusted p-values: 5.63E-06). | |||
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Sparfloxacin (adjusted p-values: 6.43E-06). | |||
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Sparfloxacin (adjusted p-values: 5.85E-06). | |||
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides ovatus was decreased by Sparfloxacin (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides thetaiotaomicron was decreased by Sparfloxacin (adjusted p-values: 1.43E-05). | |||
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides uniformis was decreased by Sparfloxacin (adjusted p-values: 6.45E-07). | |||
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides vulgatus was decreased by Sparfloxacin (adjusted p-values: 3.21E-06). | |||
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides xylanisolvens was decreased by Sparfloxacin (adjusted p-values: 4.93E-07). | |||
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Odoribacter splanchnicus was decreased by Sparfloxacin (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides distasonis was decreased by Sparfloxacin (adjusted p-values: 2.73E-07). | |||
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides merdae was decreased by Sparfloxacin (adjusted p-values: 5.04E-06). | |||
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Prevotella copri was decreased by Sparfloxacin (adjusted p-values: 5.67E-05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bifidobacterium was decreased by Sparfloxacin. | |||
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium adolescentis was decreased by Sparfloxacin (adjusted p-values: 1.73E-04). | |||
Studied Microbe: Bifidobacterium longum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium longum was decreased by Sparfloxacin (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Collinsella aerofaciens was decreased by Sparfloxacin (adjusted p-values: 2.73E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eggerthella lenta was decreased by Sparfloxacin (adjusted p-values: 6.51E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
Studied Microbe: Escherichia
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Escherichia was decreased by Sparfloxacin. | |||
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli ED1a was decreased by Sparfloxacin (adjusted p-values: 5.22E-06). | |||
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli IAI1 was decreased by Sparfloxacin (adjusted p-values: 4.93E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
Studied Microbe: Erysipelatoclostridium ramosum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Erysipelatoclostridium ramosum was decreased by Sparfloxacin (adjusted p-values: 2.17E-04). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Blautia obeum was decreased by Sparfloxacin (adjusted p-values: 1.71E-05). | |||
Studied Microbe: Clostridioides difficile
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridioides difficile was decreased by Sparfloxacin (adjusted p-values: 6.38E-04). | |||
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Clostridium was decreased by Sparfloxacin. | |||
Studied Microbe: Clostridium difficile
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Clostridium difficile was not significantly changed by Sparfloxacin. | |||
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridium perfringens was decreased by Sparfloxacin (adjusted p-values: 7.77E-07). | |||
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Coprococcus comes was decreased by Sparfloxacin (adjusted p-values: 3.84E-05). | |||
Studied Microbe: Enterocloster bolteae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Enterocloster bolteae was decreased by Sparfloxacin (adjusted p-values: 1.54E-05). | |||
Studied Microbe: Eubacterium
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Eubacterium was not significantly changed by Sparfloxacin. | |||
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium eligens was decreased by Sparfloxacin (adjusted p-values: 6.68E-06). | |||
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eubacterium rectale was decreased by Sparfloxacin (adjusted p-values: 1.92E-03). | |||
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Roseburia intestinalis was decreased by Sparfloxacin (adjusted p-values: 6.02E-04). | |||
Studied Microbe: Ruminococcus gnavus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Ruminococcus gnavus was decreased by Sparfloxacin (adjusted p-values: 9.81E-05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterococcus was decreased by Sparfloxacin. | |||
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Lactobacillus was not significantly changed by Sparfloxacin. | |||
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Lactobacillus paracasei was decreased by Sparfloxacin (adjusted p-values: 7.50E-07). | |||
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Streptococcus was not significantly changed by Sparfloxacin. | |||
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus parasanguinis was decreased by Sparfloxacin (adjusted p-values: 6.84E-07). | |||
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus salivarius was decreased by Sparfloxacin (adjusted p-values: 5.51E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
Studied Microbe: Veillonella
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Veillonella was not significantly changed by Sparfloxacin. | |||
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Veillonella parvula was decreased by Sparfloxacin (adjusted p-values: 5.04E-06). |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bacterial DNA gyrase (Bact gyrase) | Target Info | Modulator | [4] |
Staphylococcus Topoisomerase IV (Stap-coc parC) | Target Info | Modulator | [4] |
References | Top | |||
---|---|---|---|---|
REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020677. | |||
REF 2 | Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother. 1994 Mar;38(3):455-9. | |||
REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.